Drugs / RIMTUZALCAP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04301284 | Jun 2021 → Nov 2022 | Machado-Joseph disease, autosomal recessive cerebellar ataxia, spinocerebellar ataxia 7, spinocerebellar ataxia type 1 +5 | Cadent Therapeutics | Withdrawn | No outcome recorded |
| Phase 2 | NCT03688685 | Jan → Sep 2019 | essential tremor | Cadent Therapeutics | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RIMTUZALCAP | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650330 ↗ |
| Known as | CAD-1883 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03688685 ↗ |
| Action | Activate | “Positive modulation of the small-conductance calcium-activated potassium channels (SK) present in different regions of the brain aims to increase the channel sensitivity to calcium” NCT03688685 ↗ |
| Modality | Small molecule | — CHEMBL4650330 ↗ |
| Route | Oral | “administered twice daily orally” NCT03688685 ↗ |